Phase 3 Sleep Disorders Trial, Recruiting (NCT07484217)

Phase 3 Sleep Disorders Trial, Recruiting NCT07484217 Sponsor: Axsome Therapeutics, Inc. Condition: Sleep Disorders

Printed from Voxsanity (voxsanity.com.au) — NCT07484217 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sleep Disorders

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Major Depressive Disorder (depression) without psychosis, confirmed through a structured clinical interview
You experience excessive sleepiness during the daytime
You are able to follow the study procedures and attend required appointments
You are male or female, between 18 and 65 years old (inclusive)

Who may not be able to join:

You have another significant medical condition (such as sleep apnea or narcolepsy), behavioral condition, or mental health condition beyond depression with daytime sleepiness
You are unable to follow the study procedures or meet the study requirements
The study doctor believes, for medical reasons, that it would not be appropriate for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 2123325061

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07484217

Sponsor: Axsome Therapeutics, Inc.

Phase: Phase 3

Status: Recruiting

Condition: Sleep Disorders

Trial contact: 2123325061

More information: https://clinicaltrials.gov/study/NCT07484217

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Major Depressive Disorder (depression) without psychosis, confirmed through a structured clinical interview
You experience excessive sleepiness during the daytime
You are able to follow the study procedures and attend required appointments
You are male or female, between 18 and 65 years old (inclusive)

Who may not be able to join:

You have another significant medical condition (such as sleep apnea or narcolepsy), behavioral condition, or mental health condition beyond depression with daytime sleepiness
You are unable to follow the study procedures or meet the study requirements
The study doctor believes, for medical reasons, that it would not be appropriate for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Axsome Therapeutics, Inc.

Registry

ClinicalTrials.gov

Start date

23 February 2026

Est. completion

1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time from randomization to relapse of depressive symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov